A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

NCT04660643 · Completed

Last updated 2026-05-28

This study is testing whether the medication tirzepatide can help people with obesity or overweight maintain weight loss over 88 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 783 people

Who can join Ages 18+ · all sexes

Timeline Started 2021-03 · est. completion 2023-05

Where 70 sites · Argentina, Brazil, Puerto Rico, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT04660643 ↗

Description as written by the study sponsor.

This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Other

Administered SC

Main thing measured	Percent Change From Randomization in Body Weight at Week 88
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04660643 ↗